Showing results (161-170 of 183) with videos related to
Sort By:
Pageof 19
Circulation|September 8, 2005
Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in childrenZhao Yang, Colin J McMahon, Liana R Smith, et al.Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery|July 4, 2019
Increased complications without neurological benefit are associated with prophylactic spinal cord untethering prior to scoliosis surgery in children with myelomeningoceleHannah E Goldstein, Belinda Shao, Peter J Madsen, et al.Eukaryotic Cell|August 11, 2004
Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screeningAndrea Sussman, Karen Huss, Li-Chun Chio, et al.Journal of the American Heart Association|October 8, 2021
Health Care Policy and Congenital Heart Disease: 2020 Focus on Our 2030 FutureDevyani Chowdhury, Jonathan N Johnson, Carissa M Baker-Smith, et al.Cancer Research|August 17, 2005
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenograftsJeremy R Graff, Ann M McNulty, Kimberly Ross Hanna, et al.Journal of Medicinal Chemistry|March 5, 2008
Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agentHong-Yu Li, William T McMillen, Charles R Heap, et al.Molecular Cancer Therapeutics|December 21, 2013
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activityRobert M Campbell, Bryan D Anderson, Nathan A Brooks, et al.The Journal of Bone and Joint Surgery. American Volume|May 17, 2013
Evaluating the extent of clinical uncertainty among treatment options for patients with early-onset scoliosisJacqueline Corona, Daniel J Miller, Jenny Downs, et al.Bioorganic & Medicinal Chemistry Letters|November 18, 2004
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluationCarlos Jaramillo, J Eugenio de Diego, Chafiq Hamdouchi, et al.Bioorganic & Medicinal Chemistry Letters|October 14, 2003
Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitorsConcha Sanchez-Martinez, Chuan Shih, Margaret M Faul, et al.Pageof 19